Direct Selective Laser Trabeculoplasty for Glaucoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a laser procedure called Direct Selective Laser Trabeculoplasty (DSLT) to determine its effectiveness in lowering eye pressure in individuals with primary open angle glaucoma. The main focus is to compare eye pressure before treatment and six months after, without any glaucoma medications. The trial seeks adult participants of Black African descent diagnosed with mild to moderate primary open angle glaucoma who are not currently using any eye pressure-lowering medications. As an unphased study, this trial offers a unique opportunity to contribute to innovative research that could lead to new treatment options for glaucoma.
Will I have to stop taking my current medications?
Yes, you will need to stop taking your current glaucoma medications before the procedure, as the trial requires participants to have a 'washed out' eye pressure, meaning no glaucoma medications at the time of the procedure.
What prior data suggests that Direct Selective Laser Trabeculoplasty is safe for treating glaucoma?
A previous study demonstrated that Direct Selective Laser Trabeculoplasty (DSLT) is safe for patients. DSLT is a laser treatment used to lower eye pressure in people with glaucoma. Research has shown that most patients tolerate DSLT well. These studies have reported no major safety issues. Some patients might experience mild discomfort or temporary redness in the eye after the procedure, but these effects usually resolve quickly. Overall, DSLT is considered a safe option for reducing eye pressure in glaucoma patients.12345
Why are researchers excited about this trial?
Direct Selective Laser Trabeculoplasty (DSLT) is unique because it offers a non-invasive laser treatment that specifically targets the trabecular meshwork, the area responsible for draining fluid from the eye. Unlike traditional treatments for glaucoma, such as eye drops or surgery, DSLT aims to enhance fluid drainage without the need for incisions or ongoing medication use. Researchers are excited about this treatment because it has the potential to lower eye pressure effectively and safely, providing a promising alternative for patients seeking less invasive options.
What evidence suggests that Direct Selective Laser Trabeculoplasty is effective for lowering eye pressure in glaucoma?
Research has shown that Direct Selective Laser Trabeculoplasty (DSLT), the treatment under study in this trial, can effectively lower eye pressure in people with glaucoma. Studies indicate that DSLT can reduce intraocular pressure by more than 20%. Lowering eye pressure is crucial because it helps slow glaucoma progression and prevents vision loss. DSLT resembles another procedure, Selective Laser Trabeculoplasty (SLT), known for its safety and effectiveness. Unlike SLT, DSLT does not require a contact lens on the eye, potentially offering more comfort for patients. These promising findings support DSLT's potential as a treatment for glaucoma.12367
Are You a Good Fit for This Trial?
This trial is for adult, non-Caucasian patients with primary open-angle glaucoma. It's designed to see if a procedure called Direct Selective Laser Trabeculoplasty (DSLT) can lower eye pressure. Participants will need to have their vision and eye pressure checked several times after the procedure.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo the Direct Selective Laser Trabeculoplasty (DSLT) procedure in one or both eyes
Follow-up
Participants visit the clinic to have their vision and eye pressure measured
What Are the Treatments Tested in This Trial?
Interventions
- Direct Selective Laser Trabeculoplasty (DSLT)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Select Eye Care
Lead Sponsor